Chengdu Newray Medical Technology

Chengdu Newray Medical Technology is a clinical-stage biopharmaceutical company based in China, specializing in the development and commercialization of innovative radiopharmaceuticals and nuclear medicine products. Founded in 2016, the company focuses on high-end radioactive drugs for the diagnosis and treatment of various cancers, including liver, prostate, and neuroendocrine tumors. Its core pipeline includes Yttrium-90 glass microspheres and several targeted radioligand therapies utilizing isotopes like Lutetium-177 and Gallium-68. Newray Medical integrates research, production, and clinical application to address unmet medical needs in oncology. The company has established a comprehensive radiopharmaceutical production base in Chengdu and is advancing multiple programs through clinical trials in China. It aims to become a leading global player in the field of nuclear medicine by leveraging its integrated platform for isotope production and drug development.